Axe Compute Engages Cardiff Advisory LLC to Review Helomics Biobank Assets
Axe Compute has engaged Cardiff Advisory LLC to explore strategic alternatives for its Helomics Business, a CLIA-certified biobank with 150,000 tumor samples and 20 years of drug response data across 137 subtypes. The review seeks to monetize these non-core assets while concentrating on advancing the company's AI compute infrastructure strategy.
1. Strategic Review Launch
Axe Compute has retained Cardiff Advisory LLC to assist its Board of Directors in exploring strategic alternatives for the Helomics Business. The process may include a sale, partnership, licensing agreement, joint venture or other transactions designed to maximize shareholder value.
2. Helomics Business Overview
The Helomics unit operates a CLIA-certified laboratory and biobank platform containing approximately 150,000 live and frozen tumor samples, 40,000 FFPE tissue blocks, over 200,000 pathology slides and digital images, and two decades of historical drug response data spanning 137 tumor subtypes.
3. Focus on AI Compute Strategy
The strategic review underscores Axe Compute’s commitment to concentrate resources on its Aethir-powered decentralized GPU infrastructure, aiming to accelerate deployment of bare-metal AI compute services for enterprise and research customers worldwide.
4. Potential Outcomes and Next Steps
There is no guarantee the review will result in a transaction. The company will announce any approved course of action once its Board finalizes recommendations or deems further disclosure necessary.